Table 2.
Associations of telomere length‐associated variants and lung cancer risk after excluding rs2736100
| SNP | Lung adenocarcinoma | Lung squamous cell carcinoma | Overall | ||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95%CI | P | OR | 95%CI | P | OR | 95%CI | P | |
| Genetic risk score exclude rs2736100a | 1.66 | (1.27,2.16) | 1.65 × 10−4 | 1.06 | (0.71,1.58) | .784 | 1.45 | (1.15,1.84) | 1.70 × 10−3 |
| MR(IVW)exclude rs2736100b | 1.70 | (1.30,2.23) | 1.26 × 10−4 | 1.06 | (0.69,1.62) | .795 | 1.50 | (1.18,1.91) | 1.12 × 10−3 |
| Heterogeneityc | .116 | .048 | .091 | ||||||
a
Genetic risk score ORs refer to a 1‐kb increase in telomere length after excluding rs2736100.
b
Inverse variance weighted Mendelian randomization estimate for a 1‐kb increase in telomere length after excluding rs2736100.
c
Test for significant heterogeneity across the nine SNP instruments used in the Mendelian randomization analysis after excluding rs2736100.